2,5-二氨基己二酸 | 1069-33-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2,5-二氨基己二酸
• 英文名称: 2,5-diaminohexanedioic acid
• 英文别名: 2,5-diaminoadipic acid；optically inactive 2,5-diamino-adipic acid；Opt.-inakt.2,5-Diamino-adipinsaeure；2,5-Diamino-adipinsaeure；α.δ-Diamino-butan-α.δ-dicarbonsaeure；α.α'-Diamino-adipinsaeure；1.4-Diamino-butan-dicarbonsaeure-(1.4)；2.5-Diamino-hexandisaeure
• CAS: 1069-33-6
• 化学式: C₆H₁₂N₂O₄
• 分子量: 176.172
• InChiKey: KLNKMGPJWOMQTJ-UHFFFAOYSA-N

物化性质

• 熔点：
  280 °C
• 沸点：
  416.4±45.0 °C(Predicted)
• 密度：
  1.410±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -6.2
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  127
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  2,5-二氨基己二酸 在 六甲基磷酰三胺 、 正丁基锂 、 三乙胺 、 二异丙胺 、 乙酰氯 、 三氟乙酸 、 potassium iodide 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.08h， 生成 dimethyl (2S,5S)-2,5-diamino-2,5-bis[4-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)butyl]hexanedioate
  参考文献：
  名称：

  Biomimetic Design Results in a Potent Allosteric Inhibitor of Dihydrodipicolinate Synthase from Campylobacter jejuni

  摘要：

  Dihydrodipicolinate synthase (DHDPS), an enzyme required for bacterial peptidoglycan biosynthesis, catalyzes the condensation of pyruvate and beta-aspartate semialdehyde (ASA) to form a cyclic product which dehydrates to form dihydrodipicolinate. DHDPS has, for several years, been considered a putative target for novel antibiotics. We have designed the first potent inhibitor of this enzyme by mimicking its natural allosteric regulation by lysine, and obtained a crystal structure of the protein inhibitor complex at 2.2 angstrom resolution. This novel inhibitor, which we named "bislysine", resembles two lysine molecules linked by an ethylene bridge between the alpha-carbon atoms. Bislysine is a mixed partial inhibitor with respect to the first substrate, pyruvate, and a noncompetitive partial inhibitor with respect to ASA, and binds to all forms of the enzyme with a K-i near 200 nM, more than 300 times more tightly than lysine. Hill plots show that the inhibition is cooperative, indicating that the allosteric sites are not independent despite being located on opposite sides of the protein tetramer, separated by approximately 50 angstrom. A mutant enzyme resistant to lysine inhibition, Y110F, is strongly inhibited by this novel inhibitor, suggesting this may be a promising strategy for antibiotic development.

  DOI：

  10.1021/jacs.5b12695
• 作为产物：
  描述：

  dimethyl 2,5-bis(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)hexanedioate 在 氢溴酸 、 溶剂黄146 作用下， 以 水 为溶剂， 反应 336.0h， 以96%的产率得到2,5-二氨基己二酸
  参考文献：
  名称：

  Biomimetic Design Results in a Potent Allosteric Inhibitor of Dihydrodipicolinate Synthase from Campylobacter jejuni

  摘要：

  Dihydrodipicolinate synthase (DHDPS), an enzyme required for bacterial peptidoglycan biosynthesis, catalyzes the condensation of pyruvate and beta-aspartate semialdehyde (ASA) to form a cyclic product which dehydrates to form dihydrodipicolinate. DHDPS has, for several years, been considered a putative target for novel antibiotics. We have designed the first potent inhibitor of this enzyme by mimicking its natural allosteric regulation by lysine, and obtained a crystal structure of the protein inhibitor complex at 2.2 angstrom resolution. This novel inhibitor, which we named "bislysine", resembles two lysine molecules linked by an ethylene bridge between the alpha-carbon atoms. Bislysine is a mixed partial inhibitor with respect to the first substrate, pyruvate, and a noncompetitive partial inhibitor with respect to ASA, and binds to all forms of the enzyme with a K-i near 200 nM, more than 300 times more tightly than lysine. Hill plots show that the inhibition is cooperative, indicating that the allosteric sites are not independent despite being located on opposite sides of the protein tetramer, separated by approximately 50 angstrom. A mutant enzyme resistant to lysine inhibition, Y110F, is strongly inhibited by this novel inhibitor, suggesting this may be a promising strategy for antibiotic development.

  DOI：

  10.1021/jacs.5b12695

文献信息

• Novel compounds and methods for synthesis and therapy
  申请人：——

  公开号：US20040053999A1

  公开（公告）日：2004-03-18

  Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

  描述了新化合物。这些化合物通常包括一个酸性基团，一个碱性基团，一个取代氨基或N-酰基和一个具有可选择羟基化的烷基部分的基团。还描述了包括本发明的抑制剂的药物组合物。还描述了在疑似含有神经氨酸酶的样品中抑制神经氨酸酶的方法。还描述了抗原材料、聚合物、抗体、本发明化合物与标记物的结合物以及用于检测神经氨酸酶活性的测定方法。
• Method and compositions for identifying anti-HIV therapeutic compounds
  申请人：Arimilli N. Murty

  公开号：US20050239054A1

  公开（公告）日：2005-10-27

  Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

  提供了一种识别含有羧酸酯或磷酸酯基团取代的抗HIV治疗化合物的方法。可以选择使用新型酶GS-7340酯水解酶对这类化合物库进行筛选。还提供了与GS-7340酯水解酶相关的组合物和方法。
• Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
  申请人：The Ohio State University Research Foundation

  公开号：US20140100173A1

  公开（公告）日：2014-04-10

  The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer.

  这项发明提供了与钌化合物结合的含腈基蛋白酶抑制剂。这些腈基蛋白酶抑制剂与钌化合物结合后形成失活的抑制剂，可以通过光照等方式被释放到表面或部位进行激活。该发明还提供了将蛋白酶抑制剂传递给受试者以治疗癌症等疾病的方法。
• Compounds for Control of Appetite
  申请人：Balasubramaniam Ambikaipakan

  公开号：US20080221038A1

  公开（公告）日：2008-09-11

  This invention relates generally to peptides including tripeptides and to methods for pharmaceutical treatment of mammals using such tripeptides and analogs thereof. More specifically, the invention is directed to neuropeptide Y (“NPY”) receptor antagonists and agonists including O-glycosylated tripeptides, i.e. O-glycopeptides, and extended tripeptides, and their analogs, as well as to PYY analogs, to pharmaceutical compositions containing such tripeptides and PYY analogs, and to methods of treatment of mammals using such tripeptides and PYY analogs. In addition, the invention relates to methods of treatment of mammals using such tripeptides and PYY analogs for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm.

  这项发明涉及一般的肽包括三肽以及使用这些三肽及其类似物对哺乳动物进行药物治疗的方法。更具体地，该发明涉及神经肽Y（“NPY”）受体拮抗剂和激动剂，包括O-糖基化三肽，即O-糖肽，以及扩展三肽及其类似物，以及PYY类似物，包括含有这些三肽和PYY类似物的药物组合物，以及使用这些三肽和PYY类似物对哺乳动物进行治疗的方法。此外，该发明涉及使用这些三肽和PYY类似物进行治疗的方法，用于控制食欲、血压、心血管反应、性欲和昼夜节律。
• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。